However, preventive therapies are interesting in this case because CSTs are known to develop at high frequency and multiplicity in individuals with actinic keratosis or in patients treated with some immunosuppressants, antifungal antibiotics, or antitumoral therapies (i.e., B-Raf (ID number: 109880) inhibitors) [46]. This evidence concerns the gene BRAF and actinic keratosis.